Brookline Capital Markets Believes CTI BioPharma (NASDAQ: CTIC) Still Has Room to Grow

In a report released yesterday, Leah R. Cann from Brookline Capital Markets assigned a Buy rating to CTI BioPharma (CTICResearch Report), with a price target of $7.00. The company’s shares closed last Monday at $3.60, close to its 52-week high of $4.03.

According to, Cann is a 4-star analyst with an average return of 12.9% and a 50.0% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Kura Oncology, and MEI Pharma.

Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $6.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.03 and a one-year low of $0.62. Currently, CTI BioPharma has an average volume of 3.46M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.